Growth Metrics

Idexx Laboratories (IDXX) EBIT Margin (2016 - 2025)

Idexx Laboratories has reported EBIT Margin over the past 17 years, most recently at 28.94% for Q4 2025.

  • Quarterly results put EBIT Margin at 28.94% for Q4 2025, up 152.0% from a year ago — trailing twelve months through Dec 2025 was 31.6% (up 265.0% YoY), and the annual figure for FY2025 was 31.6%, up 265.0%.
  • EBIT Margin for Q4 2025 was 28.94% at Idexx Laboratories, down from 32.11% in the prior quarter.
  • Over the last five years, EBIT Margin for IDXX hit a ceiling of 33.62% in Q2 2025 and a floor of 20.81% in Q2 2022.
  • Median EBIT Margin over the past 5 years was 29.88% (2022), compared with a mean of 29.25%.
  • Biggest five-year swings in EBIT Margin: plummeted -1057bps in 2022 and later soared 1058bps in 2023.
  • Idexx Laboratories' EBIT Margin stood at 24.86% in 2021, then increased by 10bps to 27.34% in 2022, then dropped by 0bps to 27.21% in 2023, then increased by 1bps to 27.42% in 2024, then increased by 6bps to 28.94% in 2025.
  • The last three reported values for EBIT Margin were 28.94% (Q4 2025), 32.11% (Q3 2025), and 33.62% (Q2 2025) per Business Quant data.